Novetra Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.70 M
- Revenue Growth -37.56%
- Profit Growth 119.97%
- Ebitda 189.30%
- Net Worth 35.89%
- Total Assets 1.87%
About Novetra Laboratories
Novetra Laboratories Private Limited (NLPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 06 April 2017 (Seven years and ten months 8 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹0.70 M.
Nikhil Homkar and Vinayak Jotrao serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74999MH2017PTC293529
-
Company No.
293529
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Apr 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Novetra Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikhil Homkar
|
Director | 06-Apr-2017 | Current |
|
Vinayak Jotrao
|
Director | 25-Mar-2022 | Current |
Financial Performance of Novetra Laboratories.
Novetra Laboratories Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 37.56% decrease. The company also saw a substantial improvement in profitability, with a 119.97% increase in profit. The company's net worth Soared by an impressive increase of 35.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novetra Laboratories?
In 2021, Novetra Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.70 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Sep 2018 | Bank Of India | ₹0.70 M | Open |
How Many Employees Work at Novetra Laboratories?
Unlock and access historical data on people associated with Novetra Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novetra Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novetra Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
